[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-436046-en":59,"doc-seo-436046-105":80},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":8,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":72,"language_code":73,"site_id":74,"html_lang":73,"table_of_contents":75,"faqs":76,"seo_title":77,"seo_description":66,"update_tm":78,"read_time":79},436046,137441390410,"Hazel","https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","Insufficient pretransplant induction therapy is associated with diffuse intrahepatic cholangiopathy in ABO-incompatible living donor liver transplantation for acute liver failure","Background: ABO-incompatible liver transplantation (ABOi LT) can now be performed with standard induction therapy, achieving long-term outcomes comparable to ABO-compatible (ABOc) LT. Limited induction time in urgent cases of acute liver failure (ALF) requires further evaluation. Methods: Adults receiving living donor liver transplantation at Taipei Veterans General Hospital (2004–2023) were stratified by disease chronicity and transplant type into four outcome groups. Results and Conclusions address diffuse intrahepatic cholangiopathy (DIC), survival, and graft-loss risk factors.","J Chin MedAssoc  \nOriginal article  \nInsufficient pretransplant induction therapy is associated with diffuse intrahepatic cholangiopathy in ABO-incompatible living donor liver transplantation for acute liver failure  \nChih-Yao Hua,b, Cheng-Yen Chena,b, Hsin-Lin Tsaia,b,c, Hao-Jan Leia,b,d, Yi-Fan Tsoua,b, Fang-Cheng Kuoa,b, Pei-Chin Tsaia,b, Meng-Hsuan Chunga,b, Shu-Cheng Chouc,b, Shen-Chih Wangb,e, Cheng-Yuan Hsiaa,b,d, Che-Chuan Loonga,b, Chin-Su Liua,b,c, Niang-Cheng Lina,b,*  \naDivision of Transplantation Surgery, Department of Surgery, Taipei Veterans General Hospital, Taiwan, ROC; bSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC; cDivision of Pediatric Surgery, Department of Surgery, Taipei Veterans General Hospital, Taiwan, ROC; dDivision of General Surgery, Department of Surgery, Taipei Veterans General Hospital, Taiwan, ROC; eDepartment of Anesthesiology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC  \nAbstract  \nBackground: ABO-incompatible liver transplantation (ABOi LT) can now be successfully performed using standard pretransplant induction therapy. ABOi LT can achieve long-term outcomes comparable to those of blood type-compatible (ABOc) LT. The outcomes of patients with acute liver failure (ALF) undergoing urgent transplantation surgery with a limited induction period require further investigation. Methods: Between 2004 and 2023, adult patients who underwent living donor liver transplantation (LDLT) at Taipei Veterans General Hospital were included in this study. Patients were categorized into four groups for outcome analysis based on the chronicity of liver disease and transplant type. ALF patients who received ABOi LDLT, ALF patients who received ABOc LDLT, ESLD patients who received ABOi LDLT, and ESLD patients who received ABOc LDLT.  \nResults: Diffuse intrahepatic cholangiopathy (DIC) was observed in four cases within the ABOi LDLT group (n = 3, 27.3% in group 1; n = 1, 2 .6% in group 3; p = 0 .03) . In ABOi LDLT patients, rituximab was administered closer to LT in group 1 (5 [3-6] days before LDLT) than that in group 3 (15 [14-22] days before LDLT) (p \u003C 0 .01) . Univariate analysis identified ALF, a small graft-to-recipient weight ratio (GRWR), a low rituximab dose (\u003C210 mg/m²), and postoperative rebound of isoagglutinin immunoglobulin M (IgM) antibody titers as factors associated with an increased risk of DIC. Three out of four patients with DIC eventually experienced allograft loss. Overall, ABOi LDLT showed inferior long-term outcomes for ALF (5-year patient survival: 62.3%/73 .6%/74 . 1%/76 .7% in groups 1/2/3/4, respectively, p = 0 .25) . Conclusion: ABOi LDLT achieved outcomes comparable to those of ABOc LDLT among ESLD patients but not among ALF patients. DIC is associated with a high risk of allograft loss. However, the combination of potent immunosuppressive agents, early detection of antibody rebound, and timely initiation of salvage treatment may improve long-term outcomes in these patients.  \nKeywords: ABO incompatibility; Diffuse intrahepatic cholangiopathy; Liver transplantation; Living donor  \n222 [www.ejcma.org](www.ejcma.org)[ ](www.ejcma.org)\u003Cz10.1097/JCMA.0000000000001211>  \nOriginal Article. (2025) 88:3 J Chin MedAssoc  \n1. INTRODUCTION  \nLiver transplantation (LT) has become a crucial therapeutic option for individuals with end-stage liver disease (ESLD), a condition that presents significant health challenges. In Taiwan, the prominence of living donor liver transplantation (LDLT) has grown substantially, primarily due to the limited availability of deceased donor organs. The regulations governing LDLTin Taiwan are particularly stringent, limiting eligibility to individuals within a 5th-degree kinship and imposing specific physiological and psychological criteria for potential donors.1 Although these stringent regulations are designed to ensure the careful evaluation and execution of the LDLT process, they also impose limitations on its availab","cbCaiadrQfnLq8QI","https://ap.wps.com/l/cbCaiadrQfnLq8QI","pdf",979229,"English","en",105,"# Introduction\n## Background of ABO-incompatible living donor liver transplantation\n## Antibody-depletion strategies and rituximab era\n## Acute liver failure context and rationale for urgent transplantation","[{\"question\":\"What question does the study address about induction therapy in ABOi living donor liver transplantation?\",\"answer\":\"The study evaluates whether insufficient pretransplant induction therapy is associated with diffuse intrahepatic cholangiopathy in the setting of ABOi living donor liver transplantation for acute liver failure.\"},{\"question\":\"How were patients grouped for outcome analysis?\",\"answer\":\"Patients were divided into four groups based on the chronicity of liver disease (ALF vs ESLD) and transplant type (ABOi vs ABOc).\"},{\"question\":\"What factors were associated with an increased risk of diffuse intrahepatic cholangiopathy (DIC)?\",\"answer\":\"Univariate analysis identified ALF, a small graft-to-recipient weight ratio, low rituximab dose (\\u003c210 mg/m²), and postoperative rebound of isoagglutinin IgM titers as factors linked to higher DIC risk.\"}]","Insufficient pretransplant induction therapy is associated with diffuse intrahepatic cholangiopathy in ABO-incompatible living donor liver transplantation for acute liver failure | PDF",1790676548,23,{"code":4,"msg":81,"data":82},"ok",{"site_id":74,"language":73,"slug":83,"title":65,"keywords":84,"description":66,"schema_data":85,"social_meta":139,"head_meta":141,"extra_data":143,"updated_unix":144},"insufficient-pretransplant-induction-therapy-is-associated-with-diffuse-intrahepatic-cholangiopathy-in-abo-incompatible-living-donor-liver-transplantation-for-acute-liver-failure","",{"@graph":86,"@context":138},[87,101,121],{"@type":88,"itemListElement":89},"BreadcrumbList",[90,94,96,99],{"item":91,"name":92,"@type":93,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":95,"name":9,"@type":93,"position":14},"https://docshare.wps.com/document/",{"item":97,"name":40,"@type":93,"position":98},"https://docshare.wps.com/document/research-report/",3,{"item":100,"name":65,"@type":93,"position":19},"https://docshare.wps.com/document/insufficient-pretransplant-induction-therapy-is-associated-with-diffuse-intrahepatic-cholangiopathy-in-abo-incompatible-living-donor-liver-transplantation-for-acute-liver-failure/436046/",{"url":100,"name":65,"@type":102,"image":103,"author":108,"headline":65,"publisher":110,"fileFormat":113,"inLanguage":73,"description":66,"dateModified":114,"datePublished":115,"encodingFormat":113,"isAccessibleForFree":116,"interactionStatistic":117},"DigitalDocument",{"url":104,"@type":105,"width":106,"height":107},"https://docshare.wps.com/thumbnails/insufficient-pretransplant-induction-therapy-is-associated-with-diffuse-intrahepatic-cholangiopathy-in-abo-incompatible-living-donor-liver-transplantation-for-acute-liver-failure/436046.png","ImageObject",300,407,{"name":63,"@type":109},"Person",{"url":91,"name":111,"@type":112},"DocShare","Organization","application/pdf","2026-09-30","2026-09-29",true,{"@type":118,"interactionType":119,"userInteractionCount":8},"InteractionCounter",{"@type":120},"ViewAction",{"@type":122,"mainEntity":123},"FAQPage",[124,130,134],{"name":125,"@type":126,"acceptedAnswer":127},"What question does the study address about induction therapy in ABOi living donor liver transplantation?","Question",{"text":128,"@type":129},"The study evaluates whether insufficient pretransplant induction therapy is associated with diffuse intrahepatic cholangiopathy in the setting of ABOi living donor liver transplantation for acute liver failure.","Answer",{"name":131,"@type":126,"acceptedAnswer":132},"How were patients grouped for outcome analysis?",{"text":133,"@type":129},"Patients were divided into four groups based on the chronicity of liver disease (ALF vs ESLD) and transplant type (ABOi vs ABOc).",{"name":135,"@type":126,"acceptedAnswer":136},"What factors were associated with an increased risk of diffuse intrahepatic cholangiopathy (DIC)?",{"text":137,"@type":129},"Univariate analysis identified ALF, a small graft-to-recipient weight ratio, low rituximab dose (\u003C210 mg/m²), and postoperative rebound of isoagglutinin IgM titers as factors linked to higher DIC risk.","https://schema.org",{"og:url":100,"og:type":140,"og:title":65,"og:site_name":111,"og:description":66},"article",{"robots":142,"canonical":100},"index,follow",{"doc_id":61,"site_id":74},1790740830]